Stay updated on Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. The previous notices about government funding and operating status were removed.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a government funding status notice and the latest site revision tag (v3.4.1); no trial data or record content was changed.SummaryDifference0.6%

- Check28 days agoChange DetectedUI updates include a glossary toggle, green highlights for additions, red highlights for deletions, and a new revision label (Revision: v3.4.0) on the history page, with the 'No FEAR Act data' note removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check42 days agoChange DetectedThe header revision label changed from v3.3.3 to v3.3.4. This is a site version update and does not modify study data or history entries.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a new revision entry: Revision: v3.3.3 to the study history. Removed the HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry.SummaryDifference0.1%

- Check86 days agoChange DetectedAdded a new revision entry for v3.3.2 and removed v3.3.1 from the history. This updates the release version shown but does not affect study data or user-facing content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.